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1. Introduction
A kinase is an enzyme that catalyzes the transfer of phosphate moieties from 
high-energy, phosphate-donating molecules (i.e., ATP) to specific substrates that 
include proteins, lipids, carbohydrates, and nucleotides. The protein kinases act on 
proteins, via phosphorylating on serine/threonine, tyrosine, or histidine residues; 
make up the majority of all kinases; and are the most widely studied. Together, 
protein kinases and phosphatases play a major role in protein and enzyme regula-
tion as well as cellular signaling pathways [1]. More than 90 protein tyrosine kinases 
(PTKs) have been found in the human genome; 58 PTKs of about 20 families are 
receptor tyrosine kinases (RTKs), which are the high-affinity cell surface receptors 
for many growth factors, cytokines, and hormones including EGFR, PDGFR, IGFR, 
Eph, RET, and DDR; the others are non-receptor tyrosine kinases (nRTK), which 
are cytosolic enzymes and function in signal transduction pathways in activated 
immune cells [2]. Examples of nRTKs include Src, Abl, ZAP70/Syk, and JAKs and 
are separated into nine families. PTKs function as an “on” or “off” switch in many 
cellular functions; the abnormal activity of PTKs is responsible for many types of 
cancer development and progression [2–4].
Recent data from large-scale consortia such as the Cancer Genome Atlas (TCGA) 
[5] and the International Cancer Genome Consortium (ICGC) [6] have revealed 
many new mutations in kinases and authorized a robust delineation of the spectrum 
of activating kinase mutations in cancer by statistical analysis [7]. The oncogenic 
activation of PTKs is derived from many types of genetic and epigenetic changes, 
such as (1) activating point mutations, (2) chromosomal amplification, (3) chro-
mosomal alterations such as translocations or deletions, (4) epigenetic changes, 
and (5) other alterations from indirect regulatory factors including activation of 
a kinase transcription factor, inactivating mutations of negative regulators, RNA 
alternative splicing, etc. [8–10]. In fact, these multiple layers of events that result 
in constitutive activation of PTK pathways in cancer represent important and 
tractable opportunities for therapeutic intervention. Tyrosine kinase inhibitors 
(TKIs) aiming at various PTKs have thus been generated with potent anticancer 
activities. It is estimated that over 10,000 patents have been documented in the 
USA for kinase inhibitors including tyrosine and serine/threonine kinase inhibitor 
drugs since 2001 [11]. Drugs have been developed to target the extracellular domain 
or the catalytic domain, thus inhibiting ligand-binding, receptor oligomerization 
[12]. Herceptin, a monoclonal antibody that is capable of binding to the extracel-
lular domain of RTKs, has been used to treat HER2-overexpressing breast cancer 
[13]. Usually, the monoclonal antibodies are used for the targeted blockade of RTK, 
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which block the extracellular domain of the receptor and inhibit the binding of a 
ligand. For the specific inhibition on nRTKs, however, TKIs are used to block the 
signaling transduction cascade either at the intra-cytosplasmatic level or directly 
block the nRTKs [14]. Reasonably, protein kinase inhibitor drugs target and act 
upon signaling pathways that have gone awry in a given cancer, whereas all tradi-
tional chemotherapy drugs work on cell division and growth mostly leading to the 
destruction of healthy cells as the main problems in treatment of cancer patients. 
In comparison, the treatment with TKIs has fewer side effects and less time for the 
patient in the hospital. More favorably, in many cases it is feasible to screen tumor 
biopsies to see if a particular patient’s cancer has a mutation that can be targeted by 
TKI drugs [2, 12].
Up to date, the US Food and Drug Administration (FDA) has approved more 
than 30 kinase inhibitor drugs for cancer therapy; most of these target kinases are 
PTKs including ALK, BCR-Abl, BTK, c-Met, EGFR family, JAK family, MEK1/2, 
PDGFR α/β, RET, Src family, and VEGFR family; only B-raf and CDK family are 
targets of serine/ threonine kinases [11]. The aberrant PTKs promote key events 
during cancer development and progression including: (1) Tumor initiation and 
tumor transformation process. Examples of such PTKs include JAK2, ALK, IGF-1R, 
c-Kit, FGFR1-4, c-Met, c-Ret, c-Src, etc. (2) Formation of oncogenic kinase 
pathways for tumor cell survival and proliferation. The typical example is EGFR 
whose oncogenic alteration composite is ~45% of mutations in the PTK domain 
and aberrant alterations on other cytoplasmic signaling pathways such as MEK1/2, 
mTOR, and many other serine/threonine kinases. (3) The oncogenic kinases over-
expressed in both tumors and the surrounding tissues which are essential for tumor 
maintenance in the host. These include VEGFR, FGFR, BDNF receptor TrkB, etc. 
(4) Aberrant activation leading to over-expression of RTK which is a hallmark of 
cancer. These aberrant RTKs are rigorously targeted in cancer, mostly growth factor 
receptors including EGFR, VEGFR, PDGFR, etc. Several small molecule inhibitors 
and monoclonal antibodies have been approved by FDA on various RTKs for cancer 
therapies. Presently, important TKI drugs include imatinib (targeted at PDGFR, 
KIT, Abl, Arg), sorafenib (targeted at Raf, VEGFR, PDGFR, Flt3, KIT), lapatinib 
(targeted at EGFR, ErbB2), etc. [7, 11].
However, despite encouraging results, the problems with drug resistance, toxic-
ity, and even limited efficacy present critical challenges in both clinical and experi-
mental oncology. Kinase inhibition induces a strong selective pressure for cells to 
acquire resistance to the therapy through kinase mutations [15]. Therefore, the 
treatment and pathological behaviors of cancer are further complicated by second-
ary mutations that occur in different kinases [16]. Moreover, data collected from 
different centers around the world are inconsistent due to complexity of patients’ 
biopsies in temporal and spatial variations, as well as differences in data analysis 
and interpretation. Strategically, the next generation of inhibitor drugs is devel-
oped and applied with proposed better efficacy. Furthermore, drug combination 
therapies are designed and used in the treatment; some of them achieve improved 
results, yet others are likely biased toward validating well-designed targets, thereby 
limiting their capacity to prioritize novel drug targets [11]. Furthermore, many 
kinase inhibitors are associated with toxicities and off-target effects such as cardio-
toxicity, hypertension, hypothyroidism, skin reactions, and proteinuria [17, 18]. 
Especially, EGFR inhibition is associated with dermatological problems, VEGFR 
inhibition with cardiotoxicity, and HER2 and ALK inhibition with gastric irregu-
larities and dermatological issues, and BCR-ABL inhibition causes cytopenia, in 
addition to cardiotoxicity and cardiac complications [19, 20].
Kinase inhibitor drug discovery has progressed dramatically in the past decade; 
besides cancer treatment, kinase inhibitor drugs begin to be tested for the treatment 
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of other diseases such as autoimmune diseases and inflammatory disorders [21]. A 
few kinase inhibitors are first-line drugs in cancer treatment; currently, an equi-
librium which has been attained as traditional chemotherapy is still in use and in 
combination with target therapy. More and more molecules are selected as potential 
targets and developed as drug candidates; some of them are successfully applied in 
the clinics as imatinib, yet others are failed at some point during development [22]. 
Up to date, however, only a small fraction of the human kinome is being targeted, 
and therefore, besides protein kinases, lipid kinases and carbohydrate kinases, as 
well as phosphorylases and phosphatases, should be studied in analyzing the efficacy 
and resistance in cancer-targeted therapies. In future, an important strategy required 
for future development is to understand the basis of unexpected toxicities related 
to kinase inhibitors. Furthermore, there is a need to develop sophisticated modeling 
testing of chemotherapy efficacy and resistance in response to kinase inhibitors; this 
will help to overcome kinase resistance and allow for the systematic use of combina-
tions of kinase inhibitors. Additionally, advanced high-throughput cell-based screen-
ing using well-defined phosphorylation readouts should be established.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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